DC
SCLN

Deere & Company’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Deere & Company’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-27,567
Closed -$283K – 956
2016
Q3 		$283K Buy
27,567
+7,154
+35% +$77.9K 0.02% 866
2016
Q2 		$267K Sell
20,413
-5,423
-21% -$71.1K 0.01% 886
2016
Q1 		$284K Buy
+25,836
New +$230K 0.02% 797
2015
Q3 		– Sell
-12,981
Closed -$127K – 1114
2015
Q2 		$127K Hold
12,981
– – 0.01% 968
2015
Q1 		$115K Hold
12,981
– – 0.01% 950
2014
Q4 		$114K Sell
12,981
-174,437
-93% -$1.41M 0.01% 945
2014
Q3 		$1.29M Buy
+187,418
New +$1.12M 0.07% 299
2014
Q2 		– Sell
-155,252
Closed -$706K – 1075
2014
Q1 		$706K Buy
155,252
+34,010
+28% +$164K 0.04% 497
2013
Q4 		$611K Buy
121,242
+14,360
+13% +$69.1K 0.03% 619
2013
Q3 		$542K Buy
106,882
+67,847
+174% +$378K 0.03% 622
2013
Q2 		$194K Buy
+39,035
New +$186K 0.01% 875

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Deere & Company's SCLN Position: Q4 2016 in Review

Deere & Company sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2016, closing a stake of 27,567 shares — an estimated $283K sold.

Deere & Company first reported a position in SCLN in Q2 2013 and held it in 11 quarters. The position peaked at $1.29M in Q3 2014. 153 funds tracked by Wall St. Rank hold SCLN as of Q4 2016.

  • Deere & Company reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Deere & Company sold 27,567 Sciclone Pharmaceuticals Inc shares in Q4 2016, an estimated $283K.
  • Deere & Company first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 11 quarters.
  • Deere & Company's Sciclone Pharmaceuticals Inc position peaked at $1.29M in Q3 2014.
  • 153 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2016.

Based on Deere & Company's 13F filing for Q4 2016, filed 13 Feb 2017.